Lateral Flow Test Applied to Legionellosis Diagnostics
|
By LabMedica International staff writers Posted on 08 Jan 2014 |

Image: The ImmuView Legionella Lateral Flow Blood Test (Photo courtesy of Statens Serum Institut).
Early diagnosis of Legionnaires’ disease is especially important to establish the correct choice of antibiotic treatment for the patient.
The diagnosis of Legionnaires' disease has traditionally been based on culture of the bacterium Legionella pneumophila, which is quite time-consuming and has a relative low sensitivity, and on antibody detection in serum samples.
Microbiologists at the Statens Serum Institut (SSI; Copenhagen, Denmark) investigated 79 serum samples from 50 Danish patients from different parts of the country identified with Legionnaires' disease. The 50 patients consisted of 32 males, age range 33 to 85 years, and 18 females, age range 43 to 80 years. Some patients had more than one sample included, in order to follow the development of antibodies and the sensitivity of the assays.
All cases were laboratory-confirmed by different combinations of the following tests: urinary antigen test, culture, serology, and polymerase chain reaction (PCR). The samples were further investigated in four different assays: an in-house enzyme-linked immunosorbent assay (ELISA) test for L. pneumophila serogroup 1 and 3 immunoglobulins IgM/IgG antibodies, a lateral flow test called ImmuView Legionella Blood test for serogroups 1 and 3 IgM (SSI Diagnostica; Hillerød, Denmark), and two different commercial ELISAs.
Of the 79 samples, 18 samples from 16 patients were negative or borderline in all four tests. Most other samples were positive in some or all of the used tests and as expected IgM was found to be positive earlier than IgG. Overall, there is a good correlation between the results from the different tests, especially between the in-house ELISA, the lateral flow test ImmuView, and the ELISA from Virion/Serion (Würzburg, Germany). The ELISA from Euroimmun (Lübeck, Germany) did not seem to be as sensitive as the other three tests.
The authors noted that for diagnosis of legionellosis and especially Legionnaires' disease it must be remembered that antibodies to Legionella can persist for a long time after an infection and that mild and even asymptomatic infection can elicit an antibody response. Therefore, positive results should be judged in combination with the symptoms of the patient and other microbiological test results and confirmed with at least one other diagnostic method. They concluded that the lateral flow test is an easy and fast method and that the sensitivity is on the same level as ELISA based assays. Furthermore, the ImmuView seems to be more sensitive in the very early phase of disease, compared to the other commercial tests. The study was published in the January 2014 issue of the Journal of Microbiological Methods.
Related Links:
Statens Serum Institut
SSI Diagnostica
Virion/Serion
The diagnosis of Legionnaires' disease has traditionally been based on culture of the bacterium Legionella pneumophila, which is quite time-consuming and has a relative low sensitivity, and on antibody detection in serum samples.
Microbiologists at the Statens Serum Institut (SSI; Copenhagen, Denmark) investigated 79 serum samples from 50 Danish patients from different parts of the country identified with Legionnaires' disease. The 50 patients consisted of 32 males, age range 33 to 85 years, and 18 females, age range 43 to 80 years. Some patients had more than one sample included, in order to follow the development of antibodies and the sensitivity of the assays.
All cases were laboratory-confirmed by different combinations of the following tests: urinary antigen test, culture, serology, and polymerase chain reaction (PCR). The samples were further investigated in four different assays: an in-house enzyme-linked immunosorbent assay (ELISA) test for L. pneumophila serogroup 1 and 3 immunoglobulins IgM/IgG antibodies, a lateral flow test called ImmuView Legionella Blood test for serogroups 1 and 3 IgM (SSI Diagnostica; Hillerød, Denmark), and two different commercial ELISAs.
Of the 79 samples, 18 samples from 16 patients were negative or borderline in all four tests. Most other samples were positive in some or all of the used tests and as expected IgM was found to be positive earlier than IgG. Overall, there is a good correlation between the results from the different tests, especially between the in-house ELISA, the lateral flow test ImmuView, and the ELISA from Virion/Serion (Würzburg, Germany). The ELISA from Euroimmun (Lübeck, Germany) did not seem to be as sensitive as the other three tests.
The authors noted that for diagnosis of legionellosis and especially Legionnaires' disease it must be remembered that antibodies to Legionella can persist for a long time after an infection and that mild and even asymptomatic infection can elicit an antibody response. Therefore, positive results should be judged in combination with the symptoms of the patient and other microbiological test results and confirmed with at least one other diagnostic method. They concluded that the lateral flow test is an easy and fast method and that the sensitivity is on the same level as ELISA based assays. Furthermore, the ImmuView seems to be more sensitive in the very early phase of disease, compared to the other commercial tests. The study was published in the January 2014 issue of the Journal of Microbiological Methods.
Related Links:
Statens Serum Institut
SSI Diagnostica
Virion/Serion
Latest Immunology News
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







